



## Synta to Host Conference Call and Webcast of First Quarter 2015 Financial Results on May 7, 2015

April 30, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 30, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its first quarter 2015 financial results on Thursday, May 7, 2015, before market open.

Following the announcement, management will host a conference call and webcast at 10:00 a.m. ET that morning to discuss the first quarter results and provide operational updates.

The conference call can be accessed by dialing (877) 407-8035 (U.S.) or (201) 689-8035 (International). For those unable to join the live call, a replay will be available from 2:00 p.m. ET on May 7 through 11:59 p.m. ET on May 14. To access the replay, please dial (877) 660-6853 (U.S.) or (201) 612-7415 (International) and refer to conference ID 13607924.

The live [webcast](#) can be accessed by visiting the [Investor Relations](#) section of the Synta Pharmaceuticals website, [www.syntapharma.com](http://www.syntapharma.com). The webcast will also be archived under [Webcasts and Events](#) within the Investor Relations section of the Company's website.

### About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta's lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

Source: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.

Daniel Cole, 781-541-7250

[dcole@syntapharma.com](mailto:dcole@syntapharma.com)

or

Argot Partners

Andrea Rabney, 212-600-1494

[andrea@argotpartners.com](mailto:andrea@argotpartners.com)

or

Media:

Argot Partners

Eliza Schleifstein, 917-763-8106

[eliza@argotpartners.com](mailto:eliza@argotpartners.com)